Study of Gender Differences in Proton Pump Inhibitor Dose Requirements for GERD
Authors:
- 1 July 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 51 (6) , 486-493
Abstract
Goals: To determine the proportion of patients with gastroesophageal reflux disease who are on proton pump inhibitors (PPIs) who could reduce their prior dosage by half, and identify predictors of successful step-down. Background: Appropriate hypergastrinemia results from gastric acid inhibition. A gender difference in fasting gastrin with higher levels among women than among men on long-term PPI therapy has been demonstrated. Study: Patients with endoscopically verified erosive esophagitis on long-term PPI therapy were randomized double blindly to step down their dose by half or continue with the same dose for 8 weeks. Fasting gastrin levels were measured before and after treatment. The primary endpoint was successful step-down throughout the study period. Results: Overall, 100 patients were randomized, 49 (24 females) to continue with the same dose as before and 51 (25 females) to step down. Female patients had higher gastrin levels compared with male patients: 78 pg/mL (IQR, 50 to 99) versus 50 pg/mL (IQR, 36 to 74) (P=0.007). Among those randomized to the step-down intervention only 3/25 (12%) women failed to complete the 2 months of lower-dose therapy versus 9/25 (36%) men (P=0.09). Female gender (P=0.048) was the strongest predictor for successful step-down (odds ratio=1.27; 95% CI, 1.01-1.60). The chance of failing to maintain symptom control was twice as high in the reduction group (24%) as compared with the control group (13%) (P=0.2). Conclusions: Female patients on long-term PPI therapy were 3 times more likely to tolerate half of their prior dose. Female gender had higher probability for successful step-down. These results indicate that women with gastroesophageal reflux disease might manage with lower doses of PPIs as compared with men. European Clinical Trial Database (https://eudract.ema.europa.eu/), number 2013-002067-26.Keywords
This publication has 25 references indexed in Scilit:
- Proton pump inhibitor step-down therapy for GERD: A multi-center study in JapanWorld Journal of Gastroenterology, 2011
- Elevated Serum Gastrin Is Associated With a History of Advanced Neoplasia in Barrett's EsophagusAmerican Journal of Gastroenterology, 2010
- Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpointScandinavian Journal of Gastroenterology, 2009
- The development of the GERD-HRQL symptom severity instrumentDiseases of the Esophagus, 2007
- Programme of stepping down from twice daily proton pump inhibitor therapy for symptomatic gastro-oesophageal reflux disease associated with a formulary change at a VA medical centerAlimentary Pharmacology & Therapeutics, 2007
- Esomeprazole Versus Other Proton Pump Inhibitors in Erosive Esophagitis: A Meta-Analysis of Randomized Clinical TrialsClinical Gastroenterology and Hepatology, 2006
- Discontinuation of proton pump inhibitors in patients on long‐term therapy: a double‐blind, placebo‐controlled trialAlimentary Pharmacology & Therapeutics, 2006
- Review article: the long‐term use of proton‐pump inhibitorsAlimentary Pharmacology & Therapeutics, 2005
- Use of anti-secretory medication: a population-based cohort studyAlimentary Pharmacology & Therapeutics, 2004
- Marked increase in gastric acid secretory capacity after omeprazole treatment.Gut, 1996